Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT07870616
Starting soon Observational

Morbidity in Adults With Craniofacial Fibrous Dysplasia: The CRANIO-DF Study

NCT07870616 · tracked via the Priya Life Science France tracker
Sponsor
Centre Hospitalier Universitaire de Nice
Phase
Observational
Started
2026-12-01
Last updated
2026-10-13

Condition(s) studied

Craniofacial Fibrous Dysplasia

Investigational drug(s) / intervention(s)

No Intervention: Observational Cohort

No Intervention: Observational Cohort: No Intervention

Study summary

Fibrous dysplasia is a rare bone disorder in which normal bone is replaced by fibro-osseous tissue. Craniofacial involvement may be associated with substantial morbidity and complex multidisciplinary care. CRANIO-DF aims to describe morbidity, management and outcomes in adults with craniofacial fibrous dysplasia using the French national EasyHYBRID-DF database.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Age 18 years or older * Diagnosis of fibrous dysplasia recorded in HYBRID-DF * Craniofacial involvement recorded in HYBRID-DF * No objection to reuse of data for research Exclusion Criteria: * Erroneous diagnosis of fibrous dysplasia recorded in HYBRID-DF * Available data do not allow craniofacial involvement to be established

Primary outcome measure(s)

  • Presence of at least one documented morbid event or manifestation — Up to 10 years
    Binary outcome (yes/no): presence of at least one morbid event or manifestation documented in HYBRID-DF during available follow-up, including relevant bone, neurological, surgical, malignant, endocrine or other recorded morbidity.

Trial sites (1)

FacilityCityRegionStatus
CHU de Nice Nice Alpes Maritimes

More Centre Hospitalier Universitaire de Nice trials in France

AI-enhanced Imaging Analysis to Predict Post-EVAR Starting soon
Robotic Emergency General Surgery Program Starting soon
Comparison of Arterial and Capillary Blood Gas Analyses in Patients With Respiratory Distress Due to COPD or APE Recruiting
Videographic Feedback and Walk Rehabilitation in Post-Cerebrovascular Accident Recruiting
Home Based Personalized Training and Video Consultation in Mitochondrial Myopathies: Study of Efficacy and Tolerance. Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07870616 on ClinicalTrials.gov ↗ ← All trials in France